Crinetics Pharmaceuticals Hits New 52-Week High of $83.75

Crinetics Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 83.75 on July 10, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly notable given its market capitalization of USD 3,525 million, categorizing it as a small-cap stock. Over the past year, Crinetics Pharmaceuticals has demonstrated impressive growth, with a performance increase of 85.69%, significantly outpacing the S&P 500's 20.62% gain during the same period. Despite being a loss-making entity, the company continues to attract attention within its industry, characterized by a price-to-book ratio of 3.55. While the company does not offer dividends, its financial metrics, including a debt-to-equity ratio of -1.03 and a return on equity of -46.90%, reflect its current operational stance. The stock's previous 52-week low was recorded at USD 25.83, highlighting the substantial upward movement in its price. This recent high marks a pivotal moment for Crinetics Pharmaceuticals as it continues to navigate the competitive landscape of the biotechnology industry.